Two Eye-Catching Stocks : Houston American Energy Corporation (NYSE:HUSA) & ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC)

28

Houston American Energy Corporation (NYSE:HUSA)

HOUSTON AMERICAN ENERGY CORP. is an oil and gas exploration and production company. The firm’s oil and gas exploration and production activities are focused on properties in the U.S. onshore Gulf Coast Region, principally Texas and Louisiana, and on the development of concessions in the South American country of Colombia. The company generally seek to form partnerships and joint ventures to spread the cost and risks of drilling while maximizing its potential returns. Since the Company’s inception it has focused on maintaining a low overhead while utilizing the expertise and knowledge of outside consultants and industry partners on an as needed basis. Generally speaking each of their exploration projects differs in scope and character and consists of one or more types of assets, such as 3-D seismic data, leasehold positions, lease options, working interest in leases, partnership or limited liability company interest or other mineral rights.

Houston American Energy Corporation (NYSE:HUSA)’s Financial Overview

Houston American Energy Corporation (NYSE) surged 2.22% yesterday to close its trading session at $0.2. Houston American Energy Corporation has 52-Week high of $0.47 and 52-Week Low of $0.18. The stock touched its 52-Week High on 0.47 and 52-Week Low on 0.17. The stock traded with the volume of 118596 shares yesterday. The firm shows the market capitalization of $12.4 Million.

The firm is trading with SMA20 of 2.55 Percent, SMA50 of -6.59 Percent and SMA200 of -14.58 percent. Houston American Energy Corporation has P/S value of 5.39 while its P/B value stands at 1.69. Similarly, the company has Return on Assets of -10.3 percent, Return on Equity of -10.6 percent and Return on Investment of -25.7 Percent. The company shows Gross Margin and Operating Margin of 61.5 percent and -21.6 percent respectively.

The Stock currently has Analyst’ mean Recommendation of 0 where the scale is from 1 to 5, 1 means Strong Buy and 5 means Sell.

The 1 analysts offering 12-month price forecasts for Houston American Energy Corp have a median target of 11.00, with a high estimate of 11.00 and a low estimate of 11.00. The median estimate represents a +5,318.72% increase from the last price of 0.20.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC)

ImmunoCellular Therapeutics, Ltd. operates as a development stage company with primary focus on the development and commercialization of new therapeutics to fight cancer using the immune system. Its product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies targeting cancer stem cells, and monoclonal antibodies to diagnose and treat several different cancers. ImmunoCellular Therapeutics, Ltd. is based in California, USA.

ImmunoCellular Therapeutics, Ltd. (NYSE:IMUC)’s Financial Outlook

The 2 analysts offering 12-month price forecasts for ImmunoCellular Therapeutics Ltd have a median target of 42.50, with a high estimate of 80.00 and a low estimate of 5.00. The median estimate represents a +223,584.21% increase from the last price of 0.02.

Our vendor, Zacks Investment Research, hasn’t provided us with the upcoming earnings report date.

According to Zacks Investment Research, ImmunoCellular Therapeutics, Ltd. has a Consensus Recommendation of 0. (The Scale is from 1-5 where 1 means Strong Buy and 5 means Strong Sell).

The Stock surged 5.56% and closed its last trading session at $0.02. The company has the market capitalization of $800000. The stock has 52-week high of $0.36 and 52-Week low of $0.014. The firm touched its 52-Week high on 0.36 and 52-Week low on 0.01. The company has volume of 158462 shares. The company has a total of 41.91 Million shares outstanding.

ImmunoCellular Therapeutics, Ltd. (NYSE) in the last quarter reported its actual EPS of $-0.4/share where the analyst estimated EPS was $-0.61/share. The difference between the actual and Estimated EPS is $0.21. This shows a surprise factor of 34.4 percent.

The company has YTD performance of 11.76 percent. Beta for ImmunoCellular Therapeutics, Ltd. stands at -0.31 while its ATR (average true range) is 0. The company has Weekly Volatility of 15.75%% and Monthly Volatility of 27.94%%.

ImmunoCellular Therapeutics, Ltd. has distance from 20-day Simple Moving Average (SMA20) of -4.86%, Distance from 50-Day Simple Moving Average of -30.03 percent and Distance from 200-Day Simple Moving Average of -89.53%.

The Company currently has ROA (Return on Assets) of -158.6 percent, Return on Equity (ROE) of -321.9 Percent and Return on Investment (ROI) of 0% with Gross margin of 0 percent and Operating & Profit margin of 0% and 0% respectively.

SHARE